Skip to main content

Table 5 SBRT of abdominal lymph node oligometastases

From: Stereotactic body radiation therapy for abdominal oligometastases: a biological and clinical review

  Patients (N) Primary cancer Dose (Gy) × fr Median follow up (mos) Outcomes
Jereczek-Fossa et al. 2009 [53] 14 Prostate 33 (mean) × 3-5 Mean 18.6 - No in-field clinical progression
      - Distant or regional LN progression at mean time of 12.7 mo
      - All patients with relapse had high-risk disease
Bignardi et al. 2011 [54] 19 CRC (5/19) 45 × 6 12 Actuarial rate of freedom from local progression: 77.8 ± 13.9 at both 12 and 24 mos
      Minimal acute and chronic toxicity
Choi et al. 2010 [55] 30 Uterus and cervix EBRT: 27–45 (n = 4 pts) 15 4-year LC rate: 67.4%
    SBRT: 33–45 × 3 (n = 24 pts)   4-year OS rate: 50.1%
      (all 30 pts).
Kim et al. 2009 [56] 7 Gastric (salvage aftersurgery) 48 (median) × 3 26 Complete response: n = 5
      Partial response: n = 2
Kim et al. 2009 [57] 7 CRC Escalated dose 36–51 × 3 26 Median survival: 37 mos
      1-year OS: 100%
      3-year OS: 71.4%
      G4: intestinal obstruction in 1/7 patients
Bae et al. 2012 [51] 41 CRC 48(45 – 60) × 3 28 -PFS, LC and OS rates
      3-year rates : 40%, 64%, 60%
      5-year rates : 40, 57%, 38%
      -G3 perforation after pelvic LN SBRT;G4 obstruction of para-aortic LN SBRT
  1. EBRT: electron beam radiotherapy; CRC: colorectal cancer; LN: lymph node; LC: local control, OS: overall survival, G: grade.